Moraxella catarrhalis: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
Shanshan Cen (talk | contribs) No edit summary |
||
| Line 25: | Line 25: | ||
The peak rate of colonisation by ''M. catarrhalis'' appears to occur at approximately 2 years of age, with a striking difference in colonisation rates between children and adults (very high to very low). | The peak rate of colonisation by ''M. catarrhalis'' appears to occur at approximately 2 years of age, with a striking difference in colonisation rates between children and adults (very high to very low). | ||
Current research priorities involve trying to find a suitable [[vaccine]] for this genotypically diverse organism, as well as determining factors involved with virulence e.g. [[complement (biology)|complement]] resistance. | Current research priorities involve trying to find a suitable [[vaccine]] for this genotypically diverse organism, as well as determining factors involved with virulence e.g. [[complement (biology)|complement]] resistance. | ||
==Treatment== | |||
===Antimicrobial regimen=== | |||
== References == | == References == | ||
| Line 35: | Line 38: | ||
[[Category:Proteobacteria]] | [[Category:Proteobacteria]] | ||
[[Category:Infectious Disease Project]] | |||
[[de:Moraxella catarrhalis]] | [[de:Moraxella catarrhalis]] | ||
Revision as of 19:38, 7 July 2015
| Moraxella catarrhalis | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
| ||||||||||||||
| Binomial name | ||||||||||||||
| Moraxella catarrhalis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Moraxella catarrhalis is a gram-negative, aerobic, oxidase-positive diplococcus which may both colonise and cause respiratory tract-associated infection in humans.
M. catarrhalis was previously placed in a separate genus named Branhamella. The rationale for this was that other members of the genus Moraxella are rod-shaped and rarely caused infections in humans. However results from DNA hybridization studies and 16S rRNA sequence comparisons were used to justify inclusion of the species catarrhalis in the genus Moraxella. Consequently, the name Moraxella catarrhalis is currently preferred for these bacteria. Nevertheless, some in the medical field continue to call these bacteria Branhamella catarrhalis.
Clinically, these bacteria are known to cause bronchitis, sinusitis, laryngitis and otitis media. Elderly patients and long-term heavy smokers with chronic pulmonary disease should be aware that M. catarrhalis is associated with bronchopneumonia, as well as exacerbations of existing chronic obstructive pulmonary disease (COPD).
Treatment options include antibiotic therapy or a so-called "watchful waiting" approach. The great majority of clinical isolates of this organism produce beta-lactamases and are resistant to penicillin, with some suggestion of trimethoprim resistance in certain regions of the world. It is susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), fluoroquinolones, and most second and third generation cephalosporins. In addition, M. catarrhalis infection may be treated with erythromycin and amoxicillin-clavulanate (Augmentin®).
The peak rate of colonisation by M. catarrhalis appears to occur at approximately 2 years of age, with a striking difference in colonisation rates between children and adults (very high to very low).
Current research priorities involve trying to find a suitable vaccine for this genotypically diverse organism, as well as determining factors involved with virulence e.g. complement resistance.
Treatment
Antimicrobial regimen
References
- Murray, P (2005). Medical Microbiology (5th ed. ed.). Mosby. pp. p. 365. ISBN 0-323-03303-2. Unknown parameter
|coauthors=ignored (help)
- Tierney, L.; et al. (October 19, 2005). Current Medical Diagnosis and Treatment (45th ed. ed.). McGraw Hill Medical. pp. p. 1501. ISBN 0-07-145410-1.
de:Moraxella catarrhalis fa:موراکسلا کاتارالیس nl:Moraxella catarrhalis